Docetaxel-carboxymethylcellulose nanoparticles ameliorate CCl 4 -induced hepatic fibrosis in mice.

MLA

Chang, Chih-Chun, et al. “Docetaxel-Carboxymethylcellulose Nanoparticles Ameliorate CCl 4 -Induced Hepatic Fibrosis in Mice.” Journal of Drug Targeting, vol. 26, no. 5–6, June 2018, pp. 516–24. EBSCOhost, https://doi.org/10.1080/1061186X.2017.1419358.

APA

Chang, C.-C., Yang, Y., Gao, D.-Y., Cheng, H.-T., Hoang, B., Chao, P.-H., Chen, L.-H., Bteich, J., Chiang, T., Liu, J.-Y., Li, S.-D., & Chen, Y. (2018). Docetaxel-carboxymethylcellulose nanoparticles ameliorate CCl 4 -induced hepatic fibrosis in mice. Journal of Drug Targeting, 26(5–6), 516–524. https://doi.org/10.1080/1061186X.2017.1419358

Chicago

Chang, Chih-Chun, Yang Yang, Dong-Yu Gao, Hui-Teng Cheng, Bryan Hoang, Po-Han Chao, Ling-Hsuan Chen, et al. 2018. “Docetaxel-Carboxymethylcellulose Nanoparticles Ameliorate CCl 4 -Induced Hepatic Fibrosis in Mice.” Journal of Drug Targeting 26 (5–6): 516–24. doi:10.1080/1061186X.2017.1419358.